Eli Lilly and Co. will invest up to $1.8 billion to modernize its research and manufacturing facilities in Indianapolis. The multi-year project expands capacity for active pharmaceutical ingredients and injectable drug manufacturing.
A new specialized hub will focus on purifying complex peptides used in the company's latest therapies. The expansion also includes new warehousing and automated material handling systems to manage increased production.
The company is not seeking state or local incentives for the project. This investment aims to meet growing product demand and strengthen its local manufacturing footprint.